Cite
HARVARD Citation
van der Heijde, D. et al. (2022). Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Annals of the rheumatic diseases. 81 (11), pp. 1515-1523. [Online].